Urogenital Tuberculosis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Urogenital Tuberculosis – Comprehensive Medical Guide

Urogenital Tuberculosis – A Comprehensive Medical Guide

Overview

Urogenital tuberculosis (UGTB), also called genitourinary tuberculosis, is an infection of the urinary tract and/or the reproductive organs caused by Mycobacterium tuberculosis. It is the third most common form of extrapulmonary tuberculosis, accounting for 5–10 % of all TB cases and up to 20 % of extrapulmonary manifestations.1

UGTB can affect anyone infected with TB, but certain groups are more vulnerable:

  • Adults aged 20‑50 years (peak incidence in the third decade)
  • People with a history of pulmonary TB or latent infection
  • Individuals with immunosuppression (HIV, diabetes, chronic kidney disease, anti‑TNF therapy)
  • Men are slightly more frequently affected than women (≈ 1.5 : 1), though women often present with pelvic disease.

Globally, the World Health Organization (WHO) estimates 10 million new TB cases each year; about 15 % are extrapulmonary, and of those, roughly 1‑2 % involve the genitourinary system.2 In high‑burden countries (India, China, South Africa), UGTB may represent a larger proportion due to delayed diagnosis of pulmonary disease.

Symptoms

Because UGTB progresses slowly, symptoms may be vague and develop over months to years. The presentation differs by organ involved.

Kidney (renal) TB

  • Flank or back pain – often dull, unilateral, worsening at night.
  • Hematuria – intermittent or persistent blood in urine.
  • Painful urination (dysuria) – less common than in bladder disease.
  • Frequent urination or urgency.
  • Fever, night sweats, weight loss – systemic TB signs.
  • Renal insufficiency – progressive loss of kidney function if untreated.

Bladder (cystitis) TB

  • Persistent irritation, burning, or urgency.
  • Terminal hematuria (blood at the end of voiding).
  • Reduced bladder capacity leading to frequent small‑volume voids.
  • Pelvic discomfort.

Prostatic, epididymal, or testicular TB (men)

  • Painful swelling of the scrotum or testicle.
  • Firm, indurated nodule that may be mistaken for a tumor.
  • Low‑grade fever and malaise.

Female pelvic TB (fallopian tubes, uterus, ovaries)

  • Painful pelvic mass or chronic lower‑abdominal pain.
  • Infertility or menstrual irregularities.
  • Vaginal discharge or post‑coital bleeding (rare).
  • Systemic symptoms (fever, weight loss).

General/Constitutional Symptoms

  • Fever (often low‑grade, evening spikes)
  • Night sweats
  • Unexplained weight loss
  • Fatigue

Causes and Risk Factors

UGTB results from hematogenous spread of M. tuberculosis from a primary pulmonary focus, or less commonly, direct extension from adjacent organs.

Primary Causes

  • Latent or active pulmonary TB – bacteria travel via bloodstream to the kidneys, later descending the urinary tract.
  • Reactivation of dormant bacilli in the genitourinary tract years after initial infection.
  • Iatrogenic spread – rare cases after urinary instrumentation if proper sterilization is not observed.

Risk Factors

  • HIV infection (risk multiplied 10‑30×) 3
  • Diabetes mellitus – impairs macrophage function.
  • Chronic renal failure or dialysis – frequent urologic procedures.
  • Immunosuppressive therapy (TNF‑α inhibitors, corticosteroids).
  • Living or traveling in TB‑endemic regions.
  • Previous history of TB (treated or untreated).

Diagnosis

Diagnosing UGTB requires a high index of suspicion because urine cultures for M. tuberculosis are often negative early in disease. A combination of clinical, laboratory, imaging, and sometimes histopathologic data is used.

Initial Evaluation

  • Detailed history – prior TB exposure, constitutional symptoms, urinary or pelvic complaints.
  • Physical examination – flank tenderness, scrotal swelling, pelvic mass.

Laboratory Tests

  • Urine Microscopy & Culture – three early‑morning specimens; acid‑fast bacilli (AFB) smear has low sensitivity (≈ 30 %). Culture on Lowenstein‑Jensen or liquid media (MGIT) is the gold standard, taking 2‑8 weeks.
  • Nucleic Acid Amplification Tests (NAAT) – GeneXpert MTB/RIF detects DNA and rifampin resistance within hours; sensitivity ~70‑80 % for urine samples.
  • Urine PCR for TB – useful when culture is unavailable.
  • Complete blood count, ESR/CRP – nonspecific markers of inflammation.

Imaging Studies

  • Ultrasound – first‑line for bladder wall thickening, renal masses, scrotal lesions.
  • CT urogram – shows calyceal irregularities, cavities, papillary necrosis, or ureteral strictures.
    • <
  • IVU (Intravenous urography) – classic “lobar” or “moth‑eaten” calyceal patterns, though largely replaced by CT.
  • MRI pelvis – superior for soft‑tissue delineation in female genital TB.

Endoscopic & Histologic Confirmation

  • Cystoscopy – visualizes ulcerative or nodular bladder lesions; biopsies can be taken.
  • Urine cytology – may reveal granulomatous inflammation.
  • Renal or pelvic biopsy – shows caseating granulomas; special stains (Ziehl‑Neelsen) confirm AFB.

Diagnostic Criteria (Simplified)

UGTB is diagnosed when any of the following is present:

  1. Positive urine culture or NAAT for M. tuberculosis + compatible clinical picture.
  2. Histopathology showing caseating granulomas + TB detected elsewhere.
  3. Radiologic findings typical for TB **and** evidence of active pulmonary TB.

Treatment Options

Management follows the same principles as pulmonary TB, but duration is often longer (6‑12 months) and may require surgical intervention for structural complications.

Pharmacologic Therapy

According to WHO and CDC guidelines, the standard first‑line regimen is:

  • Intensive phase (2 months) – Isoniazid (INH) 5 mg/kg, Rifampin (RIF) 10 mg/kg, Pyrazinamide (PZA) 15–20 mg/kg, Ethambutol (EMB) 15–20 mg/kg (often abbreviated as HRZE).
  • Continuation phase (4–7 months) – INH + RIF (HR). In many urogenital cases, a total of 9‑12 months is recommended to ensure sterilization of renal tissue.

For drug‑resistant disease (MDR‑TB or XDR‑TB), second‑line agents (fluoroquinolones, linezolid, bedaquiline, etc.) are used per specialist consultation.

Adjunctive Measures

  • Hydration – maintain high urine output to flush necrotic debris.
  • Analgesia – NSAIDs or acetaminophen for pain; avoid nephrotoxic drugs if renal function is compromised.
  • Vitamin B6 (pyridoxine) – 25–50 mg daily to prevent INH‑induced neuropathy.

Surgical & Interventional Procedures

Surgery is reserved for complications or when medical therapy alone cannot restore function.

  • Ureteric stenting or percutaneous nephrostomy – to relieve obstruction from strictures.
  • Partial or total nephrectomy – indicated for non‑functional kidneys, large cavities, or persistent infection.
  • Bladder reconstruction (augmentation cystoplasty) – for severely contracted bladder.
  • Scrotal or epididymal excision – for isolated testicular TB not responding to drugs.

Lifestyle & Supportive Care

  • Adherence counseling – directly observed therapy (DOT) improves cure rates.
  • Nutrition – high‑protein, calorie‑dense diet to counter weight loss.
  • Smoking cessation – smoking impairs immune response and healing.

Living with Urogenital Tuberculosis

Successful treatment hinges on consistency and monitoring. Here are practical tips for day‑to‑day management:

Medication Adherence

  • Set a daily alarm or use a pill‑box.
  • Enroll in a DOT program or smartphone‑based adherence app.
  • Report any side effects (e.g., visual changes, liver pain) promptly.

Monitoring Kidney Function

  • Baseline and monthly serum creatinine, eGFR.
  • Avoid nephrotoxic drugs (NSAIDs, aminoglycosides) unless medically necessary.

Managing Urinary Symptoms

  • Drink ≥2 L of water daily unless fluid restriction is prescribed.
  • Empty bladder regularly; consider timed voiding for urgency.
  • Use soothing agents (e.g., cranberry juice, if no contraindication) for mild irritation.

Fertility Considerations

  • Men: Post‑treatment semen analysis; surgical correction may be required for obstructive azoospermia.
  • Women: Early referral to a reproductive specialist; assisted reproductive technologies (IVF) are effective after disease remission.

Psychosocial Support

  • Join TB support groups—shared experiences reduce stigma.
  • Seek counseling if anxiety or depression emerges from chronic illness.

Prevention

Because UGTB is a manifestation of systemic TB, preventing primary infection and early treatment of pulmonary disease are key.

  • BCG vaccination – offers modest protection against disseminated TB, especially in children.
  • Screen high‑risk populations (HIV‑positive, diabetics, close contacts of TB cases) with chest X‑ray and sputum testing.
  • Complete treatment of any pulmonary TB – reduces hematogenous spread.
  • Infection control in healthcare settings – proper ventilation, UV germicidal lamps, wearing N95 masks when caring for active TB patients.
  • Safe instrumentation – sterilize all urologic equipment; use disposable catheters when possible.

Complications

If left untreated or incompletely treated, UGTB can lead to irreversible damage:

  • Renal failure – due to progressive cavitation, fibrosis, or obstructive uropathy.
  • Ureteric strictures – cause hydronephrosis and pain.
  • Contracted bladder – reduced capacity, frequent incontinence.
  • Infertility – tubal obstruction in women; epididymal blockage in men.
  • Chronic pain syndromes – post‑TB scarring.
  • Secondary bacterial infections – superimposed pyelonephritis.
  • Drug toxicity – hepatotoxicity, optic neuritis (ethambutol), peripheral neuropathy (INH).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

  • Severe flank or abdominal pain accompanied by fever > 101 °F (38.5 °C).
  • Sudden inability to pass urine (urinary retention) or intense burning with urine.
  • Visible blood clots in urine or massive hematuria.
  • Rapid swelling of the scrotum or testicle with fever (possible abscess).
  • Signs of liver injury: dark urine, yellow skin/eyes, nausea/vomiting.
  • Neurological symptoms such as tingling or weakness after weeks of INH therapy (possible neuropathy).

Timely emergency care can prevent permanent organ damage and save lives.

Sources:

  1. Maurya DK, et al. “Genitourinary tuberculosis: A review.” J Clin Diagn Res. 2020;14(5):OE01‑OE07.
  2. World Health Organization. Global Tuberculosis Report 2023. https://www.who.int
  3. CDC. “Tuberculosis (TB) and HIV.” https://www.cdc.gov
  4. Mayo Clinic. “Tuberculosis (TB).” https://www.mayoclinic.org
  5. Cleveland Clinic. “Urogenital Tuberculosis.” https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References